US 8,046,286 · Application 12/538,295 · Granted Oct 25, 2011
US 8,046,286
Systems and methods for implementing the structuring, pricing, quotation, and trading of spot synthetics (spots), spread instruments (sprints), sprints based on spots, ratio derivatives (rads), rads based on spots, and options based on these instruments
Estimated expiration
February 16, 2026
Expired 206 days ago
Earliest effective filing
Feb 16, 2006
+ 20 years
Feb 16, 2026
PTA +0d
Feb 16, 2026
No TD
—
Final
Feb 16, 2026
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- August 10, 2009
- Earliest effective filing
- February 16, 2006
- Issue date
- October 25, 2011
- PTA
- 0 days
- Base expiry (before PTA)
- February 16, 2026
February 16, 2006 + 20 years = February 16, 2026
- Continuation of application 11/354,866, filed Feb 16, 2006, issued as US 7,574,394
- PRO60/653,104 — Provisional — not used for base term
- PRO60/653,104 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 12/538,295 · US 8,046,286
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,046,286: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8046286Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.